造血細胞分化群表面抗原的基因多型性與攝護腺癌進展之相關性

Association between Hematopoietic Cell CD Marker Gene Polymorphisms and Prostate Cancer Progression

李政學(Cheng-Hsueh Lee)

指導教授 ： 黃書彬

高雄醫學大學/醫學院/臨床醫學研究所碩士班/碩士(2020年)

摘要

背景：分化群（Cluster of differentiation, CD）表面抗原是用於區分造血細胞類型的細胞表面標誌物。這些抗原存在於各種惡性腫瘤中，並且被認為與癌症患者的預後有關，但到目前為止，它們尚未被開發為可以預測攝護腺癌進展的標誌物。本研究的目標在於評估造血細胞分化群標誌物中遺傳差異，對攝護腺癌患者臨床結果的影響。

方法：首先，我們先針對458例接受過根治性攝護腺切除手術後的攝護腺癌患者，進行關聯性研究，從中尋找是否有和術後的生化復發（BCR）相關的分化群抗原基因多型性。之後，在另一組185例患者中進一步評估此預測因子。

結果：針對合併族群分析顯示，CD1B rs3181082 與生化復發相關 (校正後的風險比 1.42,95％ 信賴區間1.09-1.85，P = 0.010)。此外，rs3181082 與轉錄調控元件重疊並影響 CD1B 表達。進一步分析，低 CD1B 表達與較差的生化復發相關。

結論：我們的結果說明 CD1B rs3181082 可能促使攝護腺癌的進展，並可作為改善臨床的預後評估。

關鍵字

表面抗原分化群 ； 攝護腺癌 ； 生物標誌 ； 預後

並列摘要

Background: Cluster of differentiation (CD) antigens are cell surface markers used to differentiate hematopoietic cell types. These antigens are present in various malignancies and are thought to be linked to patient prognosis, but they have not been developed as markers for prostate cancer progression. This study aimed to assess the impact of genetic variation in hematopoietic cell CD markers on clinical outcomes in patients with prostate cancer.

Methods: An association study of 458 patients with prostate cancer was conducted to identify single-nucleotide polymorphisms in 11 candidate CD marker genes associated with biochemical recurrence (BCR) after radical prostatectomy. Identified predictors were further evaluated in an additional set of 185 patients.

Results: Joint population analyses showed that CD1B rs3181082 is associated with BCR (adjusted hazard ratio 1.42, 95% confidence interval 1.09–1.85, p = 0.010). In addition, CD1B rs3181082 overlapped with predicted transcriptional regulatory elements and affected CD1B expression. Furthermore, low CD1B expression was correlated with poorer BCR-free survival.

Conclusion: Our results indicated that CD1B rs3181082 confers prostate cancer progression and may help improve clinical prognostic stratification.

並列關鍵字

CD antigen ； Prostate cancer ； Biomarker ； Prognosis ； CD1B

參考文獻

1. Prostate Cancer. National Cancer Institute. January 1980. Archived from the original on 12 October 2014. Retrieved 12 October 2014

2. Stewart BW, Wild CP. World Cancer Report 2014. World Health Organization. 2014, Chapter 5.11.

3. Ruddon RW. Cancer Biology 2007 (4th ed.). Oxford: Oxford University Press. 2007, 223.

4. Prostate Cancer Treatment (PDQ) – Health Professional Version". National Cancer Institute. 2014-04-11. Archived from the original on 5 July 2014. Retrieved 1 July 2014

5. Dennis LK, Lynch CF, Torner JC. Epidemiologic association between prostatitis and prostate cancer. Urology 2002, 60, 78–83.